Americans at Harvard University have created genetically modified stem cells in the laboratory that can kill cancerous brain tumors.
Scientists at Harvard Medical School, quoted by BBC, explains that these cells produce toxins that kill cancer cells but that at the same time are able to withstand the effects of the poison they produce and thus do not affect other healthy cells.
This discovery is considered by experts worldwide as the future technique in treating cancer.
Treatment has already been tested on laboratory mice, and after the stem cells were surrounded in gel and placed at brain tumor, cancer cells were destroyed by toxins.
The toxins that kill malignant tumors have been successfully used in a variety of cancers of the blood, but they do not work as well in solid tumors because not all cancers are equally accessible and toxins have a short period of activity.
But now the situation is changing through genetic modification of stem cells they produce, and Agerpres reports.SZacks Investment Research upgraded shares ofStemCells Inc (NASDAQ:STEM) from a hold rating to a buy rating in a report released on Friday morning,MarketBeat.com reports. They currently have $0.25 price target on the stock.
According to Zacks, “Stemcells, Inc. is engaged in research aimed at the development of therapies that would use stem and progenitor cells derived from fetal or adult sources to treat, and possibly cure, human diseases and injuries such as Parkinson’s disease, hepatitis, diabetes, and spinal cord injuries. “
In related news, General Counsel Kenneth Blair Stratton sold 104,549 shares of the company’s stock in a transaction dated Tuesday, December 29th. The shares were sold at an average price of $0.45, for a total transaction of $47,047.05. Following the transaction, the general counsel now owns 556,525 shares in the company, valued at approximately $250,436.25. The sale was disclosed in a filing with the SEC, which can be accessed through this link.
Several other equities research analysts have also weighed in on the stock. Maxim Group reaffirmed a buy rating and issued a $3.00 target price on shares of StemCells in a report on Wednesday, December 23rd. Chardan Capital reaffirmed a buy rating and issued a $1.00 target price (down previously from $1.55) on shares of StemCells in a report on Thursday, December 24th. Finally, HC Wainwright reaffirmed a buy rating and issued a $2.10 target price on shares of StemCells in a report on Tuesday, November 24th. Seven research analysts have rated the stock with a buy rating, The stock presently has an average rating of Buy and a consensus price target of $1.54.
Shares of StemCells (NASDAQ:STEM) traded down 1.4063% during trading on Friday, hitting $0.2524. 2,162,600 shares of the stock traded hands. StemCells has a 1-year low of $0.21 and a 1-year high of $1.10. The company’s market cap is $27.46 million. The company has a 50 day moving average of $0.34 and a 200-day moving average of $0.42.
StemCells (NASDAQ:STEM) last announced its quarterly earnings results on Tuesday, March 15th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.09) by $0.01. On average, equities analysts anticipate that StemCells will post ($0.39) EPS for the current fiscal year.
StemCells, Inc is engaged in the research, development, and commercialization of stem cell therapeutics. The Company is focused on developing and commercializing stem and progenitor cells as the basis for therapeutics and therapies. The Company’s lead product development program is its CNS Program, in which it is developing applications for HuCNS-SC cells, its human neural platform technology.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for StemCells Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for StemCells Inc and related companies with MarketBeat.com's FREE daily email newsletter.
One of the authors of the study published in the journal Stem Cells, Dr. Khalid Shah said that soon will initiate laboratory tests on mice with glioblastoma, the most common type of brain tumor in humans.After completion of testing, this type of therapy would be tested on humans within 5 years.esearch carried out in the past five years have demonstrated that like any tissue of the body and starts all cancerous tissue from some stem cells.
Why is attacked brain. The most common malignant brain tumors are the result of migration of cancer cells in the body from other bodies, a phenomenon called metastasis. More rarely, cancer cells are formed directly in the brain and form the so-called primary brain tumors. They can spread along the central nervous system and spinal cord can reach. Although the exact causes are unknown, it is assumed that the genetic factor plays an essential role in brain cancer.
Diagnostic- brain tumors can be detected by computed tomography.
Noutate- discovery that tumors all come from one category of stem cells explains why, once removed surgically, cancer still persists in the body. These cells can not be detected by any normal means of diagnosis because they “hide” in the most inaccessible and yet most favorable for their development. So far scientists have discovered cancer stem cells for four forms of malignant brain tumors, myeloma (bone marrow localized), and breast cancer.
How to form cancerul- brain cancer is one of the most problematic forms of oncological diseases, it is very difficult to treat. And this explanation is quite simple: until recently not discovered the exact mechanisms of this type of tumor formation. Researchers believed that all cells forming a malignant brain tumor are identical. But little time scientists have revealed that within a group of brain tumors are cancer stem cells. In fact, these cells are those that confer malignancy tumor, molecular biologists concluded from Children’s Hospital “St. Jude “in Tennese USA.
Specifically tumors formed by the accumulation of cancer stem cells located in a kind of “niche” created by tiny blood vessels in the brain. As these cells are “fed” the blood vessels that coexist, they grow and form tumors.
Radiation is one of the causes of cancer in the brain.
In human development, stem cells (stem cells) are undifferentiated cells that have the ability mitotic division to reânoiasc? (and keep unmodified original properties of these cells), but have the ability to differentiate and generate highly specialized cells . By analogy, recent research has hypothesized that the origin of malignant cancerous tumors could stand some mutant cells with properties to divide and maintain germinal nucleus, but also to multiply and generate localized tumor masses or remotely. These cells are indicted cancer recurrences in patients treated for various cancers. Moreover, surgery is designed to extract solid masses of cancer cells and chemotherapy and radiotherapy intended to destroy these outstanding potential cancer stem cells in the body.
How stem cells survive. The specialists at Children’s Hospital “St. Jude “is now trying to find the weak point of cancer stem cells by comparing them with noncancerous neural stem cells. The latter are concentrated in brain areas rich in blood vessels, which are lined with endothelial cells. These, in turn, secrete a number of chemicals that help stem cells to survive. In this way are kept alive and cancer stem cells that are nestled near the capillaries. When the researchers injected laboratory mice stem cells from a human malignant tumor with endothelial cells, the animals developed tumors than mice that were injected only cancer stem cells.
It will create a new treatment. Once discovered the weakness of cancer stem cells, researchers can create a treatment that specifically target these cells. Therefore, experts are working on a method to be destroyed parts of the capillaries that feed the cells. It is possible that anti-angiogenic treatments (of stumbling to the formation of new blood vessels) that are to be effective.
In human development, stem cells (stem cells) are undifferentiated cells that have the ability mitotic division to reânoiasc? (and keep unmodified original properties of these cells), but have the ability to differentiate and generate highly specialized cells . By analogy, recent research has hypothesized that the origin of malignant cancerous tumors could stand some mutant cells with properties to divide and maintain germinal nucleus, but also to multiply and generate localized tumor masses or remotely. These cells are indicted cancer recurrences in patients treated for various cancers. Moreover, surgery is designed to extract solid masses of cancer cells and chemotherapy and radiotherapy intended to destroy these outstanding potential cancer stem cells in the body.
How stem cells survive. The specialists at Children’s Hospital “St. Jude “is now trying to find the weak point of cancer stem cells by comparing them with noncancerous neural stem cells. The latter are concentrated in brain areas rich in blood vessels, which are lined with endothelial cells. These, in turn, secrete a number of chemicals that help stem cells to survive. In this way are kept alive and cancer stem cells that are nestled near the capillaries. When the researchers injected laboratory mice stem cells from a human malignant tumor with endothelial cells, the animals developed tumors than mice that were injected only cancer stem cells.
It will create a new treatment. Once discovered the weakness of cancer stem cells, researchers can create a treatment that specifically target these cells. Therefore, experts are working on a method to be destroyed parts of the capillaries that feed the cells. It is possible that anti-angiogenic treatments (of stumbling to the formation of new blood vessels) that are to be effective.
No comments:
Post a Comment